(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||||||||
(Address of principal executive offices) | (Zip Code) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Item 7.01 | Regulation FD Disclosure. |
Item 8.02 | Other Events. |
Item 9.01 | Financial Statements and Exhibits. |
Exhibit No. | Description | |||||||
99.1 | ||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document contained in Exhibit 104) |
December 21, 2021 | BIODELIVERY SCIENCES INTERNATIONAL, INC. | |||||||||||||
By: | /s/ James Vollins | |||||||||||||
Name: | James Vollins | |||||||||||||
Title: | General Counsel |
U8K)]I90R]0&9E8_D37IGP5T^RM?A7I4EM&FZZ$DEPX'+OO8
M'/K@ #\*O^$/AQIOACP?=Z!-(U__ &AO-]-(-IF++M.!DX&.G/J:Y'3OAAXY
M\+";3_"WC:*WT>5RRQW%L'>//ID$9]P5SUP* )_CCJD&C^"++PY9M!9_VK<+
M $2.%2&8\=!DIGV)KE_#6J:!X6^.%I;>'M1MKG1M7LH[1C X*I*%"KG_:+
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M"KYOB;:>+KB^@81::+26%4(+2 :EK7A;4=#\2>*9-32X\MK65+&.W-J
MR$G("GYL\<'L/>H;3P7JFAW5_P"*M6UFY\1ZY!I[VUDL=JL.T8) "@G+$]_<
MT >B5XK\:/#'AM+&>]\BXN?%FK3Q1:>JSNSY!4$*F]>D^![#6--\
M':=;:_>27>J!"]Q)(VY@68MMSWV@@?A7+ZM\,M8O?'-SXJL?&+V5U(OEPJ^G
M)/\ 9TQC:A=L#OR .I]30!@7>CR:W\1?"?A#Q.S7MK8Z MS<0M(=LUQRA8D'
MYL;>OU]33? ^A:3JV@>*/#FN2ROH.AZ[,8D>X9%6)0PVLP(.T >E9MC\3M)OX["YCT[5H]/O)UMDOY;<+"LK':%8[L]>-P!7/&
M:T=1TJ]G^(.AZI'#NL[6RNHII-P&UG,6T8SDYVMT':N:A\*ZRGPET?0VL\:C
M;W=O)+#YJ?*JW(=CNS@X7G@T ='J7C6VL=3N["UTK5-4FLE5KLV$*LL&1D E
MF7+8YVKDXJS;>+M*O;C1(K1Y)EUF"6>UE1?EVQA2V[)R#\PXQU!SBL&*'Q#X
M7U_Q ]CH#ZO:ZK.=)TZRUJ\N$N1#H]U':W)6,$
M[GV8*C/(_>+GOP>#W=I/C*TU/5Y-,EL-1TZY%N;J(7\(C$T((!9<,<8)&0V"
M,]*Y"?PSXDU#P[XL6XTM(;W5-5MKJ"!+A&'EJ8"?FR!D!&STY!QD8STVMZ!>
M:GXUL[I4*V/]DW=I+.&&4>0Q[>,Y/ 8_A0!-H_C6UUNXA^RZ7JJV%QN\C49(
M +>4*":\2+
M*K,XCP?,P!G;@YKG_#=G=75QJ.AZ=++)H%UI\JRW4NC"Q\J=L* H"1^9\I8G
MCC YYH N1^+O%$/AG3M4O+72C